Recombinant 9-valent Human Papillomavirus vaccine (Shanghai Bovax Biotechnology)

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male subjects aged 18-45 years. The primary hypothesis in the study is the 9-valent HPV recombinant vaccine reduces the incidence of vaccine HPV types-related genital warts compared with placebo in Chinese men.

主要目的：评价HPV九价疫苗在9~45岁中国健康男性人群中的安全性和耐受性 次要目的：评价HPV九价疫苗在9~45岁中国健康男性人群中的免疫原性。